Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis

Arthritis and Rheumatism

Volumn 41, Issue 9, 1998, Pages 1639-1644

  Brewster, Michael ^a,b   Lewis, E Jonathan ^a   Wilson, Kevin L ^a   Greenham, Anna K ^a   Bottomley, Kevin M K ^a  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b Roche Discovery Welwyn ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPEMASTAT; COLLAGENASE; COLLAGENASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CHONDROLYSIS; DRUG EFFECT; DRUG EFFICACY; HISTOLOGY; JOINT RADIOGRAPHY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PRIORITY JOURNAL;

ANIMALS; CARTILAGE, ARTICULAR; COLLAGENASES; DISEASE MODELS, ANIMAL; IMIDAZOLES; KNEE JOINT; MALE; MICE; MICE, INBRED BALB C; MICRORADIOGRAPHY; OSTEOARTHRITIS; PROTEASE INHIBITORS;

EID: 0031654554     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199809)41:9<1639::AID-ART15>3.0.CO;2-0     Document Type: Article

References (17)

1. Peyron JG. Osteoarthritis: the epidemiologic viewpoint. Clin Orthop 1986;213:13-9.
2. Hamerman D. The biology of osteoarthritis. N Engl J Med 1989;320:1322-30.
3. Gardner DL. Gardner DL, editor. In: Pathological basis of connective tissue diseases. London: Edward Arnold; 1992. p. 842-923.
4. Resnick D, Niwayama G. Degenerative diseases of the extraspinal locations. In: Resnick D, editor. Bone and joint imaging. Philadelphia: WB Saunders; 1989. p. 379-412.
5. Adams ME, Pelletier JP. Canine anterior cruciate ligament transection model of osteoarthritis. In: Greenwald RA, Diamond HS, editors. CRC handbook of animal models in rheumatic diseases. Vol. 2. Boca Raton (FL): CRC Press; 1990. p. 57-82.
6. Walton M. Studies of degenerative joint disease in the mouse knee joint: histological observations. J Pathol 1977;123:109-22.
7. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
8. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis: easier said than done? Arthritis Rheum 37:1115-26.
9. Brinckerhoff CE. Joint destruction in arthritis: metalloproteinases in the spotlight. Arthritis Rheum 1991;34:1073-5.
10. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989;84:678-85.
11. Martel-Pelletier J, Cloutier JM, Pelletier JP. Neutral proteases in human osteoarthritic synovium. Arthritis Rheum 1986;29:1112-21.
12. Broadhurst MJ, Brown PA, Lawton G, Ballantyne N, Borkakoti N, Bottomley KM, et al. Design and synthesis of the cartilage protective agent (CPA, Ro32-3555). Bioorg Med Chem 1997;7: 2299-302.
13. Lewis EJ, Bishop J, Bottomley KM, Bradshaw D, Brewster M, Broadhurst MJ, et al. Ro32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Br J Pharmacol 1997; 121:540-6.
14. Evans RG, Collins C, Miller P, Ponsford FM, Elson CJ. Radiological scoring of osteoarthritis progression in STR/ORT mice. Osteoarthritis Cartilage 1994;2:103-9.
15. Buckland-Wright JC. Quantitative radiography in osteoarthritis. Ann Rheum Dis 1994;53:268-75.
16. Walton M. Degenerative joint disease in the mouse knee: radiological and morphological observations. J Pathol 1977;123:97-107.
17. Cashin CH, Clegg JB, Cline A, Greenham AK. Some observations on the chemotherapy of osteoarthritis in STR/ORT mice [abstract]. Br J Pharmacol 1986;89:812P.